Navigation Links
Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
Date:12/14/2009

As Abbott integrates STARLIMS into its existing portfolio of laboratory information management products, the company will continue to support and expand the non-clinical market segments currently served by STARLIMS.

"We believe our laboratory information management solutions, which are widely used by government, manufacturing and life sciences organizations, have important applications in clinical laboratories for improving the access, exchange and analysis of patient and technical data," said Itschak Friedman, chief executive officer of STARLIMS, who will continue to lead the STARLIMS team after the acquisition closes. "We look forward to becoming a part of Abbott and working together to serve our current customers and expand the availability of our technologies to address unmet needs in laboratories around the world."

Under the terms of the agreement, Abbott will acquire all outstanding equity of STARLIMS for $14 per share, for a total purchase price of approximately $123 million. STARLIMS currently has approximately $18 million in cash on hand.

This transaction does not impact Abbott's previously issued ongoing earnings-per-share guidance for 2009 and is subject to customary closing conditions. Abbott expects the transaction to close in the first quarter of 2010.

About STARLIMS Technologies Ltd.

STARLIMS Technologies Ltd. (Nasdaq: LIMS) is a leading provider of laboratory information management systems (LIMS), with approximately 160 employees worldwide and more than 20 years of LIMS experience. The company's flagship product, STARLIMS®, improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities. STARLIMS software is u
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Declares 344th Consecutive Quarterly Dividend
2. Abbott Statement on ARBITER 6 - HALTS Results and Abbotts Niaspan (niacin extended-release)
3. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
4. Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
5. Abbott Again Honored for Offering One of the Top 10 Leading Workplaces
6. Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2
7. Abbott Announces TCT 2009 Activities
8. Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts
9. Abbott Again Named One of the Best Places to Launch a Career by BusinessWeek
10. Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
11. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, ... 2014, court documents indicate that 1,183 claims had been ... developed gynecomastia (male breast growth) and other complications allegedly ... that this represents an increase of more than 100 ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company ... the company announces its multiple layer bamboo panel ... these new products. , Bamboo panel is the product ... layer bamboo panel board features high quality selective bamboo ... free. The bamboo panel consists of multiple layers of ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... be crumbling under the mounting pressure of dengue. Safdarjung ... several patients being referred to AIIMS and the Red ... patients are given platelets only on the condition of ... exchange for the required platelets. Dr Santosh at the ...
... come up with some valuable information which would definitely ... the mind of an autistic person is blue printed. ... to be affected by autism a developmental disorder typically ... people. ,Lead researcher Dr Michael Murias, from ...
... disorders in women may be diagnosed by examining hair ... It is usually difficult to diagnose eating disorders//, as ... they try to hide it. ,The study ... University (BYU) in U.S. is published in the Rapid ...
... has made a formal application to the European Medicines ... as a viable treatment// for advanced HER2-positive and hormone ... received from the international TAnDEM study which showed that ... from 2.4 months to 4.8 months. ,HER2-positive breast ...
... by NHS hospitals because they are serving meals that are ... catering at 97 health trusts. ,The survey revealed ... food brought in by relatives and friends. Over 37% of ... or tasted disgusting. ,Over a fifth of patients claimed that ...
... John Howard ,the prime minister of Australia, stirred up the ... media for the first time that she had battled ... the National Breast Cancer Centre, she was addressing an august ... all important national breast cancer report.,Over the ‘Pink Ribbon’ breakfast ...
Cached Medicine News:Health News:Mounting Pressure of Dengue in Delhi Hospitals 2Health News:Eating Disorders may be diagnosed by Hair analysis 2Health News:NHS Food Slowing Patient Recovery 2
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... MIVI-TRUST Phase III Program, Confirming... -- LEUVEN, Belgium, September 6, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10China Sky One Medical Updates Financial Guidance for 2010 2China Sky One Medical Updates Financial Guidance for 2010 3China Sky One Medical Updates Financial Guidance for 2010 4China Sky One Medical Updates Financial Guidance for 2010 5China Sky One Medical Updates Financial Guidance for 2010 6China Sky One Medical Updates Financial Guidance for 2010 7China Sky One Medical Updates Financial Guidance for 2010 8
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... the sulfate ester of DHEA, derived from ... DHEA in adrenal and extradrenal tissues. DHEA ... the adrenal cortex, and is a precursor ... relatively weak androgenic activity, which for unsulfated ...
... The DHEA-S ELISA kit is based ... separation. An unknown amount of DHEA-S present ... of DHEA-S conjugated with horse-radish peroxidase compete ... DHEA-S antiserum coated onto the wells. After ...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: